Patents by Inventor Shaun Abbott
Shaun Abbott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230113202Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.Type: ApplicationFiled: February 2, 2022Publication date: April 13, 2023Inventors: Shaun ABBOTT, Mylène DeLESELEUC, Julien MARTEL, Elyse BOURQUE, Jeremy GREEN, Alexandre LARIVÉE, Jean-Benoìt GIGUÈRE, Elodie LANDAGARAY, Claudio STURINO, Nadia Michel NASSER
-
Publication number: 20230091528Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.Type: ApplicationFiled: February 2, 2022Publication date: March 23, 2023Inventors: Shaun ABBOTT, Mylène DeLESELEUC, Julien MARTEL, Elyse BOURQUE, Jeremy GREEN, Alexandre LARIVÉE, Jean-Benoît GIGUÈRE, Elodie LANDAGARAY, Claudio STURINO
-
Patent number: 11524930Abstract: The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, F or OH; R2 is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R3 is H, F, OH or CH2Ph; R4 is H, F or OH; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH, or 6) C(O)—C(O)OH; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.Type: GrantFiled: February 3, 2020Date of Patent: December 13, 2022Assignee: LIMINAL BIOSCIENCES LIMITEDInventors: Boulos Zacharie, Shaun Abbott, Lyne Gagnon, Pierre Laurin, Brigitte Grouix
-
Patent number: 11183802Abstract: An in-floor electrical fitting includes a lower body, an upper body detachably connected to the lower body, and at least one detachable retention clip movable between a first position in which a portion of the at least one detachable retention clip extends outwardly past a periphery of the body and a second position in which the portion of the at least one detachable retention clip is moved inward from the periphery of the body. An angular position of the upper body may be reconfigurable relative to the lower body into at least two different orientations.Type: GrantFiled: December 23, 2019Date of Patent: November 23, 2021Assignee: THE WIREMOLD COMPANYInventors: Albert Carter, III, Timothy S. Bowman, Marc Galasso, Shaun Abbott
-
Publication number: 20200203899Abstract: An in-floor electrical fitting includes a lower body, an upper body detachably connected to the lower body, and at least one detachable retention clip movable between a first position in which a portion of the at least one detachable retention clip extends outwardly past a periphery of the body and a second position in which the portion of the at least one detachable retention clip is moved inward from the periphery of the body. An angular position of the upper body may be reconfigurable relative to the lower body into at least two different orientations.Type: ApplicationFiled: December 23, 2019Publication date: June 25, 2020Inventors: Albert Carter, III, Timothy S. Bowman, Marc Galasso, Shaun Abbott
-
Publication number: 20200172462Abstract: The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is O5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, F or OH; R2 is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R3 is H, F, OH or CH2Ph; R4 is H, F or OH; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH, or 6) C(O)—C(O)OH; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.Type: ApplicationFiled: February 3, 2020Publication date: June 4, 2020Inventors: Boulos ZACHARIE, Shaun ABBOTT, Lyne GAGNON, Pierre LAURIN, Brigitte GROUIX
-
Patent number: 10550066Abstract: The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, F or OH; R2 is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R3 is H, F, OH or CH2Ph; R4 is H, For OH; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH, or 6) C(O)—C(O)OH; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.Type: GrantFiled: April 4, 2018Date of Patent: February 4, 2020Assignee: PROMETIC PHARMA SMT LIMITEDInventors: Boulos Zacharie, Shaun Abbott, Lyne Gagnon, Pierre Laurin, Brigitte Grouix
-
Publication number: 20180237374Abstract: The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, F or OH; R2 is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R3 is H, F, OH or CH2Ph; R4 is H, For OH; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH, or 6) C(O)—C(O)OH; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.Type: ApplicationFiled: April 4, 2018Publication date: August 23, 2018Inventors: Boulos ZACHARIE, Shaun ABBOTT, Lyne GAGNON, Pierre LAURIN, Brigitte GROUIX
-
Patent number: 10023518Abstract: The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, F or OH; R2 is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R3 is H, F, OH or CH2Ph; R4 is H, F or OH; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH, or 6) C(O)—C(O)OH; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.Type: GrantFiled: March 14, 2014Date of Patent: July 17, 2018Assignee: PROMETIC PHARMA SMT LIMITEDInventors: Boulos Zacharie, Shaun Abbott, Lyne Gagnon, Pierre Laurin, Brigitte Grouix
-
Patent number: 9884802Abstract: The present invention relates to substituted aromatic compounds for use in prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis, where the compound has the following formula: or a pharmaceutically acceptable salt thereof, wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, OH or F; R2 is H, OH, F or CH2—OH; R3 is H, OH, F or CH2Ph; R4 is H, OH or F; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH, or 6) C(O)—C(O)OH.Type: GrantFiled: March 14, 2014Date of Patent: February 6, 2018Assignee: PROMETIC PHARMA SMT LIMITEDInventors: Lyne Gagnon, Pierre Laurin, Brigitte Grouix, Lilianne Geerts, François Sarra-Bournet, Martin Leduc, Shaun Abbott, Boulos Zacharie, Jean-François Bienvenu, Valérie Perron
-
Patent number: 9475750Abstract: Phenylketone carboxylate compounds of Formula I, wherein n=2-6; R?C(0); —OC(O)— or —CH(OH)—; A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A and B form a 5-7 membered cycloalkyl substituted with COOFt W=0, S or NFt Y=0,S,NH or CH2; m=0-2; p=1-7; have been prepared. These compounds and their pharmaceutically acceptable salts have beneficial therapeutic effects to prevent or treat a condition related to (l) blood disorders, (ii) inflammation related diseases, (iii) renal disorders and/or renal disorders complications, or (iv) fibrosis-related organ dysfunction.Type: GrantFiled: October 26, 2011Date of Patent: October 25, 2016Assignee: PROMETIC BIOSCIENCES INC.Inventors: Boulos Zacharie, Christopher Penney, Shaun Abbott, Lyne Gagnon, Brigitte Grouix, Pierre Laurin, Jean-François Bienvenu
-
Publication number: 20160039736Abstract: The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(0)-(CH2)n-CH3 or CH(OH)—(CH2)n-CH3 wherein n is 3 or 4; R1 is H, F or OH; R2 is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(0)-(CH2)n-CH3 or CH(OH)—(CH2)n-CH3 wherein n is 3 or 4; R3 is H, F, OH or CH2Ph; R4 is H, F or OH; Q is 1) (CH2)mC(0)OH wherein m is 1 or 2, 2) CH(CH3)C(0)OH, 3) C(CH3)2C(0)OH, 4) CH(F)—C(0)OH, 5) CF2-C(0)OH, or 6) C(0)-C(0)OH; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.Type: ApplicationFiled: March 14, 2014Publication date: February 11, 2016Inventors: Boulos ZACHARIE, Shaun ABBOTT, Lyne GAGNON, Pierre LAURIN, Brigitte GROUIX
-
Publication number: 20160023983Abstract: The present invention relates to substituted aromatic compounds for use in prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis, where the compound has the following formula: or a pharmaceutically acceptable salt thereof, wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, OH or F; R2 is H, OH, F or CH2—OH; R3 is H, OH, F or CH2Ph; R4 is H, OH or F; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH, or 6) C(O)—C(O)OH.Type: ApplicationFiled: March 14, 2014Publication date: January 28, 2016Inventors: Lyne GAGNON, Pierre LAURIN, Brigitte GROUIX, Lilianne GEERTS, François SARRA-BOURNET, Martin LEDUC, Shaun ABBOTT, Boulos ZACHARIE, Jean-François BIENVENU, Valérie PERRON
-
Publication number: 20130225681Abstract: Phenylketone carboxylate compounds of Formula I, wherein n=2-6; R?C(0); —OC(O)— or —CH(OH)—; A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A and B form a 5-7 membered cycloalkyl substituted with COOFt W=0, S or NFt Y=0,S,NH or CH2; m=0-2; p=1-7; have been prepared. These compounds and their pharmaceutically acceptable salts have beneficial therapeutic effects to prevent or treat a condition related to (l) blood disorders, (ii) inflammation related diseases, (iii) renal disorders and/or renal disorders complications, or (iv) fibrosis-related organ dysfunction.Type: ApplicationFiled: October 26, 2011Publication date: August 29, 2013Applicant: PROMETIC BIOSCIENCES INC.Inventors: Boulos Zacharie, Christopher Penney, Shaun Abbott, Lyne Gagnon, Brigette Grouix, Pierre Laurin
-
Publication number: 20070149528Abstract: Compounds containing two mono- or disubstituted triazine rings covalently linked by an organic linker, but not linked directly to each other, may be used to treat autoimmune diseases. Autoimmune diseases which are amenable to treatment with compounds of this invention include rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis. The present invention also relates to reducing drug toxicity which often accompanies traditional therapies for autoimmune diseases. The compounds may also be used to bind antibody in vitro or ex vivo.Type: ApplicationFiled: November 22, 2004Publication date: June 28, 2007Inventors: Christopher Penney, Boulos Zacharie, Shaun Abbott, Jean-Francois Bienvenu, Alan Cameron, Jean-Simon Duceppe, Abdallah Ezzitouni, Daniel Fortin, Karine Houde, Nancia Moreau, Nicole Wilb, Brigitte Grouix, Lyne Gagnon
-
Patent number: 6630488Abstract: The present invention is directed towards novel compounds that are effective inhibitors of integrins, particularly &agr;IIb&bgr;3 or &agr;v integrins such as &agr;v&bgr;3 and &agr;v&bgr;5. One embodiment of the present invention comprises a compound of formula (I) or formula (II) or a pharmaceutically acceptable salt, solvate, or metabolic precursor thereof. R1, R2, R3, and R4 are defined herein.Type: GrantFiled: March 20, 2001Date of Patent: October 7, 2003Assignee: Biochem Pharma, Inc.Inventors: Serge Lamothe, Boulos Zacharie, Giorgio Attardo, Denis Labrecque, Marc Courchesne, Guy Falardeau, Rabindra Rej, Shaun Abbott